Athenex Inc. (ATNX)
Symbol Info
Listed Symbol ATNX
Name Athenex Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $89,100,000
Latest Fiscal EPS $-1.80
Price Info
21 Day Moving Average $12.7810
21 Day EMA $12.589730
50 Day Moving Average $14.1722
50 Day EMA $13.927080
200 Day EMA $14.623350
200 Day Moving Average 14.014350
52 Week High $21.11
52 Week Low $9.38
52 Week Change $-18.736100
Alpha -0.001425
Beta -0.1948
Standard Deviation 0.154795
R2 0.002394
Periods 28
Share Information
10 Day Average Volume 556,827
20 Day Average Volume 734,488
30 Day Average Volume 626,333
50 Day Average Volume 721,853
Outstanding Shares 77,293,285
Float Shares 70,187,480
Percent Float 90.81%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 195
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 11,845,886
Institute Holdings Percent 62.700000
Institute Sold Previous 3 Months 1,327,346
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 4
Insider Holdings Percent 9.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned 7,105,805
Price Change
7 Day Price Change $-1.25
7 Day Percent Change -10.26%
21 Day Price Change $-3.3099995
21 Day Percent Change -23.24%
30 Day Price Change $-3.4699993
30 Day Percent Change -24.10%
Month To Date Price Change $-1.235
Month To Date Percent -10.15%
90 Day Price Change $-9.139999
90 Day Percent Change -45.54%
Quarter To Date $-1.235
Quarter To Date Percent -10.15%
180 Day Price Change $-1.06
180 Day Percent Change -8.84%
200 Day Price Change $-1.549999
200 Day Percent Change -12.42%
Year To Date $-1.759999
Year To Date Percent -13.87%
Profile
Description Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.
Details
Issue Type CS
Market Cap $844,815,605
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 77,293,285
CEO Johnson Y.N. Lau
Employees 582
Last Audit UE
Classification
CIK 0001300699
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1001 Main Street
Suite 600
Buffalo, NY 14203
Website http://www.athenex.com
Facisimile +1 716 800-6816
Telephone +1 716 427-2950
Email info@athenex.com
Key Ratios
Profitability
EBIT Margin -167.8
EBITDA Margin -163.9
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 27.70
Profit Margin TOT -
Income Statements
Revenue $68,775,000
Revenue Per Share $0.8898
Revenue 3 Years $46.16
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $861,550,812
Price To Sales 12.283761
Price To Free Cash -11.7
PE High Last 5 Years -
Price To Book 5.4
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 7.3
Financial Strength
Total Debt To Equity 0.4
Int Coverage -36.1
Current Ratio 2.6
Leverage Ratio 2.0
Quick Ratio 1.6
Long Term Debt To Capital 0.24
Assets
Receivables Turnover 3.6
Invoice Turnover 2.40
Assets Turnover 0.10
Management Effectiveness
Return Assets -56.27
Return On Equity -92.86
Return On Capital -76.81
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ATNX
Athenex
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.